Sort   by:  
 Page size 
GenomicsNanopore sequencing of cancer cell-line NCI-H1975
Nanopore sequencing of cancer cell line NCI-H1975
PRJEB47159 | ENA
TranscriptomicsGene expression profile of cell lines 2106T, H1975 and MeWo after knockdown of PAEP.
Gene expression profile was analyzed after knockdown of PAEP in lung cancer cell lines 2106T and H1975 as well as in skin cancer cell line MeWo. The aim of the study was to investigate the role of PAEP and its protein product glycodelin in lung cancer cell lines. Cells were treated with a control si...
ORGANISM(S): Homo sapiens 
2015-04-22 | E-GEOD-60888 | biostudies-arrayexpress
MetabolomicsNiacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Cell NAMPTi treatment)

NAMPT plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi...

2023-10-10 | MTBLS7251 | MetaboLights
TranscriptomicsHuman lung adenocarcinoma NCI-H1975 cells: parental vs cell lines resistant to the EGFR-TK inhibitor CNX-2006
Genome variation profiling of lung adenocarcinoma cells comparing untreated NCI-H1975 cells with CNX-2006-resistant untreated cells. Goal was to determine the potential mechanism of resistance to mutant EGFR-TKIs and rationally design novel strategies for the treatment of EGFR-mutant lung cancer pat...
ORGANISM(S): Homo sapiens 
2015-07-01 | E-GEOD-53234 | biostudies-arrayexpress
GenomicsRNA transcriptome sequencing of lung adenocarcinoma cell line H1975 treated with siNC or siHHLA3 oligonucleotides
RNA transcriptome sequencing of lung adenocarcinoma cell line H1975 treated with siNC or siHHLA3 oligonucleotides
PRJNA1205687 | ENA
UnknownHER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib.
Not available
S-EPMC5228548 | biostudies-literature
GenomicsDisclosing potential therapeutic targets associated with Osimertinib resistance in non-small cell lung cancer cell line H1975
Disclosing potential therapeutic targets associated with Osimertinib resistance in non-small cell lung cancer cell line H1975
PRJNA991974 | ENA
TranscriptomicsTranscription profiling of non-small cell lung carcinoma cell line H1975 treated with cisplatin or BMS-69014 a novel panHER/VEGFR inhibitor
Non-small cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) responds to EGFR tyrosine kinase inhibitors such as erlotinib. However, secondary somatic EGFR mutations (e.g. T790M) confer resistance to erlotinib. BMS-690514, a novel panHER/VEGFR inhibitor...
ORGANISM(S): Homo sapiens 
2007-07-24 | E-TABM-239 | biostudies-arrayexpress
UnknownCharacterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Not available
S-EPMC5348415 | biostudies-literature
TranscriptomicsRole of Anlotinib-induced CCL2 decrease in anti-angiogensis and response prediction for Non-Small Cell Lung Cancer therapy
Purpose: Our previous clinical trials have been demonstrated that Anlotinib can inhibit tumor growth upon refractory advanced non-small cell lung cancer (NSCLC) patients with the possibility mechanism of anti-angiogenesis. The present study sought to reveal the underlying molecular mechanism of Anlo...
ORGANISM(S): Homo sapiens 
2018-11-30 | E-MTAB-5997 | biostudies-arrayexpress
Sort   by:  
 Page size